Get to know our clinical trials
Trial of linvoseltamab in patients with previously untreated symptomatic multiple myeloma.
THE LONG-TERM GOAL OF THIS CLINICAL TRIAL IS TO FIND OUT WHETHER A SINGLE DRUG, LINVOSELTAMAB, CAN REPLACE THESE MULTIPLE DRUG REGIMENS. SO FAR, LINVOSELTAMAB HAS ONLY BEEN STUDIED IN CLINICAL TRIAL PARTICIPANTS WITH MYELOMA WHO HAVE RECEIVED PRIOR TREATMENT FOR THEIR DISEASE, BUT NOT IN CLINICAL TRIAL PARTICIPANTS WITH MMDR.
Technical Summary
- PHASE I/II STUDY OF LINVOSELTAMAB (BISPECIFIC ANTI-BCMA AND ANTI-CD3 ANTIBODY) IN PATIENTS WITH PREVIOUSLY UNTREATED SYMPTOMATIC MULTIPLE MYELOMA (LINKER-MM4 STUDY). IMMUNOTHERAPY
- Code EudraCT: 2022-500800-24-00
- Protocol number: R5458-ONC-2158
- Promoter: Regeneron Pharmaceuticals, Inc.
- Molecule/Drug: Linvoseltamab
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.